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Open Forum Infectious Diseases
MAJOR ARTICLE
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Background. In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of Clostridioides (Clostridium)
difficile infection (rCDI) over 12 weeks. Choice of CDI antibacterial treatment may affect CDI-related outcomes; therefore, this
prespecified analysis assessed if the magnitude of bezlotoxumab-induced rCDI reduction was influenced by the antibiotic
administered.
Methods. In MODIFY I/II (NCT01241552/NCT01513239), participants received a single infusion of bezlotoxumab (10 mg/kg)
or placebo during anti-CDI treatment. Using pooled data from MODIFY I/II, initial clinical cure (ICC) and rCDI were assessed in
metronidazole-, vancomycin-, and fidaxomicin-treated subgroups.
Results. Of 1554 participants in MODIFY I/II, 753 (48.5%) received metronidazole, 745 (47.9%) vancomycin, and 56 (3.6%)
fidaxomicin. Fewer participants receiving metronidazole had a prior CDI episode in the previous 6 months (12.9%) or ≥1 risk factor
for rCDI (66.0%) vs participants receiving vancomycin (41.2% and 83.6%, respectively) and fidaxomicin (55.4% and 89.3%, respectively). ICC rates were similar in the bezlotoxumab (metronidazole, 81.0%; vancomycin, 78.5%; fidaxomicin, 86.7%) and placebo
groups (metronidazole, 81.3%; vancomycin, 79.6%; fidaxomicin, 76.9%). In placebo-treated participants, the rCDI was lower in the
metronidazole subgroup vs the vancomycin and fidaxomicin subgroups (metronidazole, 28.0%; vancomycin, 38.4%; fidaxomicin,
35.0%). When analyzed by subsets based on history of CDI, rCDI rates were similar in the metronidazole and vancomycin groups.
rCDI rates were lower in all antibiotic subgroups for bezlotoxumab vs placebo (metronidazole: rate difference [RD], –9.7%; 95%
confidence interval [CI], –16.4% to –3.1%; vancomycin: RD, –15.4%; 95% CI, –22.7% to –8.0%; fidaxomicin: RD, –11.9%; 95% CI,
–38.1% to 14.3%).
Conclusion. Bezlotoxumab reduces rCDI vs placebo in participants receiving metronidazole and vancomycin, with a similar
effect size in participants receiving fidaxomicin.
Keywords. antibacterial drug treatment; bezlotoxumab; Clostridioides (Clostridium) difficile infection recurrence; toxin.
In recent years, Clostridioides (Clostridium) difficile has become
one of the leading causes of hospital-acquired infections in
the United States [1], with a marked increase in associated
morbidity and mortality [2–4].
For 30 years, metronidazole and vancomycin were the main
antibacterial drugs used in the treatment of C. difficile infection
(CDI); metronidazole was recommended for mild to moderate
CDI, whereas vancomycin was the preferred therapy for severe
and recurrent infections [5]. However, studies have shown that
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vancomycin results in superior clinical cure rates compared with
metronidazole in individuals with both nonsevere and severe
CDI [6, 7]. Furthermore, treatment of an initial episode with
fidaxomicin has been shown to significantly reduce the likelihood of recurrent CDI (rCDI) compared with vancomycin
[8–10]. These findings have resulted in significant revisions to
treatment guidelines, and in the 2017 Infectious Diseases Society
of America/Society of Healthcare Epidemiology of America
(IDSA/SHEA) CDI guidelines, the recommended first-line
antibacterial drug treatment for severe and nonsevere CDI was
vancomycin or fidaxomicin, rather than metronidazole [1].
Whereas antibiotic treatment of primary CDI is usually
successful in decreasing signs and symptoms of the disease,
it has been reported that ~25% of individuals will experience
rCDI after initial antibiotic therapy [6, 10]. Treatment of rCDI
remains challenging; following the first recurrent episode,
individuals have a 38% probability of a second recurrence,
despite initial episodes being treated with metronidazole or
vancomycin [11]. The likelihood of additional recurrences is
Bezlotoxumab and Anti-CDI Treatment • ofid • 1
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Efficacy of Bezlotoxumab in Participants Receiving
Metronidazole, Vancomycin, or Fidaxomicin for Treatment
of Clostridioides (Clostridium) difficile Infection

METHODS
Study Design

MODIFY I (NCT01241552) and MODIFY II (NCT01513239)
were
randomized,
double-blind,
placebo-controlled,
multicenter, phase 3 trials conducted between November 1,
2011, and May 22, 2015, at 322 sites in 30 countries. Full details
of the trials have been published previously [14]. Briefly, participants receiving metronidazole, vancomycin, or fidaxomicin for
primary or rCDI were randomized in a 1:1:1:1 ratio to receive a
single infusion of actoxumab plus bezlotoxumab (10 mg/kg of
body weight each), bezlotoxumab alone (10 mg/kg), actoxumab
alone (10 mg/kg; MODIFY I only), or placebo (0.9% saline).
Antibacterial drug treatment for the presenting CDI episode
was to be administered for a minimum of 10 days and a
maximum of 14 days in an attempt to control any influence
2 • ofid • Dubberke et al

of treatment duration on CDI-related outcomes. Initial clinical cure (ICC) was imputed as failure if treatment was given
longer than 14 days (defined as 16 calendar days to account for
partial dosing on the first and last days). Choice of antibacterial treatment for CDI was per the treating clinician’s discretion and could not be changed during the MODIFY I/II trials.
Randomization was stratified according to oral antibacterial
drug treatment (metronidazole, vancomycin, or fidaxomicin)
and hospitalization status (inpatient or outpatient) at the time
of study randomization.
MODIFY I/II were conducted in accordance with Good
Clinical Practice guidelines and the provisions of the Declaration
of Helsinki. The protocols and amendments were approved by
the institutional review board or independent ethics committee
at each study site. Written informed consent was provided by all
participants before entering the trial.
Prespecified Analysis of Pooled Data From MODIFY I/II

In this prespecified analysis of pooled data from the MODIFY
I/II trials, which includes only participants who received
bezlotoxumab alone or placebo, efficacy end points were
assessed based on the antibacterial drug administered to treat
the presenting CDI episode. The metronidazole, vancomycin,
and fidaxomicin subgroups were based on the antibacterial
drug that was entered by the investigator into the randomization system (ie, the stratification factor). In a few instances (62
participants of 1554 [4%] included in the modified intent-totreat [mITT] population), the stratification factor differed from
the antibacterial drug that the participant ultimately received.
The results reported here are based on the stratification factor
to be consistent with the original statistical analysis plan.
Efficacy End Points and Statistical Methods

The primary end point was rCDI, which was defined as a new
episode of diarrhea (≥3 unformed stools in 24 hours) associated with a positive stool test for toxigenic C. difficile within 12
weeks of bezlotoxumab or placebo infusion in participants who
had achieved ICC of the baseline CDI episode (clinical cure
population). ICC was an exploratory end point, which was defined as no diarrhea during the 2 consecutive days after completion of ≤14 days of antibacterial drug treatment. Rates of
all-cause 30-day and 90-day mortality were estimated in the allpatients-as-treated (APaT) population. The rates of all-cause
and CDI-related rehospitalization within 30 days of antibiotic
treatment were assessed in participants who were inpatients at
the time of randomization. An additional analysis using only
data from placebo participants is presented here. This analysis
explores the impact of a confounding variable (prior history
of CDI) on the assessment of rCDI in each of the antibacterial
drug cohorts.
The analysis population for ICC was the mITT population,
which included all randomized participants in the overall
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influenced by the choice of antibacterial drug treatment received. In treating a first recurrent episode, fidaxomicin has
been associated with a reduced rate of second recurrence
compared with vancomycin [9].
Bezlotoxumab is a fully human monoclonal antibody against
C. difficile toxin B that is indicated to prevent the recurrence
of rCDI in at-risk adults receiving antibacterial drug treatment for CDI [12, 13]. MODIFY I/II were global, randomized, double-blind, placebo-controlled trials of the efficacy of
bezlotoxumab for the prevention of rCDI in adults receiving
metronidazole, vancomycin, or fidaxomicin. In the MODIFY
trials, bezlotoxumab administered with or without actoxumab
(a fully human monoclonal antibody against C. difficile toxin
A) was shown to significantly lower the rate of rCDI over 12
weeks compared with placebo. The addition of actoxumab did
not improve efficacy [14].
In the MODIFY trials, the selection of metronidazole, vancomycin, or fidaxomicin to treat the presenting CDI episode
was made by the treating physician [14]. The 2010 IDSA/SHEA
CDI guidelines, which were in effect at the time of study enrollment, recommended metronidazole for the treatment of mild/
moderate CDI and vancomycin for severe CDI and multiple
rCDI [5]. Fidaxomicin was not included in the 2010 guidelines
because it was approved in 2011 [15]. Fidaxomicin became
available shortly before initiation of the MODIFY trials, and as
it is indicated for treatment of CDI, it was allowed as an antibiotic choice for these trials. As the rate of rCDI could be influenced by the antibacterial drug treatment received for the
presenting CDI episode, treatment groups were stratified at the
time of randomization according to this variable in both trials.
Given the potential influence of the antibacterial drug
treatment received on rCDI, this prespecified analysis examined if the administration of metronidazole, vancomycin, or
fidaxomicin had an impact on efficacy outcomes in participants
receiving bezlotoxumab or placebo in the MODIFY I/II trials.

RESULTS
Participants

The integrated mITT population from MODIFY I/II consisted
of 1554 participants, of whom 781 received bezlotoxumab and
773 received placebo. The majority of participants received
oral metronidazole or oral vancomycin. Across both treatment
groups, 753 (48.5%) participants were in the metronidazole
stratum, 745 (47.9%) were in the vancomycin stratum, and 56
(3.6%) were in the fidaxomicin stratum. By design, the proportions of participants receiving bezlotoxumab and placebo were
similar in each antibacterial drug treatment subgroup (Table 1).
The mean number of calendar days of antibacterial treatment before infusion with the study agent was similar between
subgroups (metronidazole, 3.3 days; vancomycin, 3.2 days;
fidaxomicin, 3.0 days), as was the mean total duration of
antibacterial treatment (metronidazole, 13.6 days; vancomycin,
14.5 days; fidaxomicin, 11.9 days). Across all subgroups, the
number of days on antibacterial treatment before infusion
ranged from 0 to 14 days and the total number of treatment
days ranged from 2 to 87 days. (Table 1).
Although many participant characteristics were generally similar between the metronidazole, vancomycin, and
fidaxomicin subgroups, there were some notable differences.
Compared with participants who received metronidazole, participants who received vancomycin were of an older age (median
age [range], 62 [49–75] years vs 67 [56–78] years; ≥65 years:
45.6% vs 57.1%), more likely to have ≥1 episode of CDI in the
past 6 months (12.9% vs 41.2%), more likely to have ≥1 predefined risk factor for rCDI (66.0% vs 83.6%), more likely to be
an inpatient at the time of infusion (64.8% vs 71.7%), and more
likely to have severe disease at baseline (Zar Score ≥2: 13.3% vs
18.7%) (Table 2). Compared with the metronidazole and vancomycin subgroups, participants in the fidaxomicin subgroup
were more likely to have ≥1 episode of CDI ever (metronidazole, 16.9%; vancomycin, 46.0%; fidaxomicin, 69.6%). Notably,
21.4% of participants in the fidaxomicin subgroup had ≥3 prior
CDI episodes, compared with 2.3% and 9.1% of metronidazoleand vancomycin-treated participants, respectively (Table 2).
Initial Clinical Cure

ICC rates were similar across antibiotic strata in the placebo group
(metronidazole, 81.3%; vancomycin, 79.6%; fidaxomicin, 76.9%)

Table 1. Administered Antibacterial Drug Treatment for CDI According to
Treatment Group (mITT Population)

Metronidazole stratum
(48.5% of participants)
Oral metronidazole alone

Bezlotoxumab
(N = 781), n (%)

Placebo
(N = 773), n (%)

379

374

361 (95.3)

344 (92.0)

Oral metronidazole with IV
metronidazole

7 (1.8)

2 (0.5)

Othera

11 (2.9)

28 (7.5)

Days on antibacterial
treatment before infusionb
  Mean (SD)
  Median (range)

3.4 (2.1)

3.1 (2.1)

3 (0 to 13)

3 (0 to 11)

Total days on antibacterial
treatmentb,c
  Mean (SD)

13.4 (3.5)

13.7 (4.9)

14 (2 to 37)

13 (5 to 62)

372

373

Oral vancomycin alone

318 (85.5)

300 (80.4)

Oral vancomycin with
IV metronidazole

44 (11.8)

52 (13.9)

Othera

10 (2.7)

21 (5.6)

  Median (range)
Vancomycin stratum
(47.6% of participants)

Days on antibacterial
treatment before infusionb
  Mean (SD)
  Median (range)

3.2 (2.2)

3.3 (2.1)

3 (0 to 14)

3 (–1 to 13)

Total days on antibacterial
treatmentb,c
  Mean (SD)
  Median (range)
Fidaxomicin stratum
(3.8% of participants)
Oral fidaxomicin alone

14.7 (7.7)

14.3 (5.1)

14 (4 to 87)

14 (3 to 67)

30

26

26 (86.7)

24 (92.3)

Oral fidaxomicin with IV
metronidazole

1 (3.3)

1 (3.8)

Othera

3 (10.0)

1 (3.8)

Days on antibacterial
treatment before infusionb
  Mean (SD)
  Median (range)

3.0 (2.9)

3.0 (2.2)

2 (0 to 12)

3 (0 to 8)

Total days on antibacterial
treatmentb,c
  Mean (SD)
  Median (range)

11.8 (2.3)

12.0 (2.3)

11 (10 to 20)

11 (10 to 21)

Abbreviations: CDI, Clostridioides difficile infection; IV, intravenous; mITT, modified
intent-to-treat.
a

The actual antibacterial drug treatment for CDI on the day of infusion differed from the
stratification antibacterial drug treatment for CDI.
b

Data represent the number of calendar days.

c

Data for total days on antibacterial treatment reflect the days on therapy for all antibiotics
given to treat the CDI episode under treatment at the time of randomization and include
days before, the day of, and days after administration of study medication.

and the bezlotoxumab group (metronidazole, 81.0%; vancomycin,
78.5%; fidaxomicin, 86.7%). There was no difference in ICC
rates between participants receiving bezlotoxumab and placebo,
regardless of whether metronidazole, vancomycin, or fidaxomicin
was administered to treat the presenting CDI episode (metronidazole: rate difference [RD], –0.3%; 95% CI, –5.9% to 5.3%;
Bezlotoxumab and Anti-CDI Treatment • ofid • 3
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population of the MODIFY I/II trials who received the study infusion, had a positive baseline stool test for toxigenic C. difficile,
and initiated antibacterial drug treatment before, or within
1 day after, the study infusion [14].
Observed rates of ICC and rCDI are presented, along
with rate differences between the bezlotoxumab and placebo
groups and their 95% confidence intervals (CIs). The 95% CIs
are based on the Miettinen and Nurminen method without
stratification [16].

Table 2. Baseline Demographics and Clinical Characteristics in
Treatment Groups (mITT Population)

Metronidazole
Stratum
(N = 753), n (%)

Vancomycin
Stratum
(N = 745),
n (%)

Fidaxomicin
Stratum
(N = 56), n (%)

Mean (SD)

60.6 (18.4)

64.9 (16.8)

61.3 (18.4)

Median (IQR)

62 (49–75)

67 (56–78)

63 (54–72)

≥65 years

343 (45.6)

426 (57.2)

26 (46.4)

≥75 years

194 (25.8)

244 (32.7)

10 (17.9)

Female

433 (57.5)

422 (56.6)

36 (64.3)

Inpatient at the time
of randomization

488 (64.8)

534 (71.7)

28 (50.0)

Immunocompromiseda

165 (21.9)

155 (20.8)

11 (19.6)

≥1 of 5 predefined
risk factors for rCDIb

497 (66.0)

623 (83.6)

50 (89.3)

Charlson Comorbidity
Index ≥3

304 (40.4)

288 (38.7)

30 (53.6)

Renal impairmentc

7 (12.5)

113 (15.0)

113 (15.2)

Hepatic impairmentd

43 (5.7)

47 (6.3)

3 (5.4)

≥1 CDI episodes in past
6 months

97 (12.9)

307 (41.2)

31 (55.4)

≥1 CDI episode ever

127 (16.9)

342 (45.9)

39 (69.6)

0

613 (81.4)

388 (52.1)

17 (30.4)

1

93 (12.4)

178 (23.9)

11 (19.6)

2

17 (2.3)

96 (12.9)

16 (28.6)

Number of prior CDI
episodes

17 (2.3)

68 (9.1)

12 (21.4)

Severe CDI
(Zar Scoree ≥2)

≥3

100 (13.3)

139 (18.7)

8 (14.3)

Participants with a
positive culture

517 (68.7)

431 (57.9)

28 (50.0)

Ribotype 027, 078,
or 244

89 (11.8)

121 (16.2)

7 (12.5)

Ribotype 027

72 (9.6)

111 (14.9)

6 (10.7)

Abbreviations: ALT, alanine aminotransferase; CDI, Clostridioides difficile infection; IQR,
interquartile range; mITT, modified intent-to-treat; rCDI, recurrent C. difficile infection; ULN,
upper limit of normal; WBC, white blood cell.
a

Defined as the basis of a participant’s medical history or use of immunosuppressive therapy.

b

Predefined risk factors include CDI history in the past 6 months, severe CDI at baseline
(per Zar score), age ≥65 years, having a hypervirulent strain (027, 078, or 244 ribotypes) at
baseline, and being immunocompromised.
c

Serum creatinine ≥1.5 mg/dL.

d

Based on 2 or more of the following: (1) albumin ≤3.1 g/dL; (2) ALT ≥2X ULN; (3) total
bilirubin ≥1.3X ULN; or (4) mild, moderate, or severe liver disease (as reported on the
Charlson comorbidity index).
e
Based on the following: (1) age >60 years (1 point); (2) body temperature >38.3˚C (>100˚F;
1 point); (3) albumin level <2.5 mg/dL (1 point); (4) peripheral WBC count >15 000 cells/
mm3 within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2
points); and (6) treatment in intensive care unit (2 points).

vancomycin: RD, –1.1%; 95% CI, –7.0% to 4.7%; fidaxomicin:
RD, 9.7%; 95% CI, –11.0% to 31.3%). Similar ICC rates were also
observed in the overall study results, with no difference in the
rate between bezlotoxumab-treated (80.0%) and placebo-treated
participants (80.3%; RD, –0.3%; 95% CI, –4.3% to 3.7%) (Figure 1).
CDI Recurrence

Differences Between Antibacterial Treatment Subgroups

In placebo-treated participants, 28.0% of participants in the
metronidazole subgroup experienced rCDI compared with
4 • ofid • Dubberke et al

Differences Between Bezlotoxumab and Placebo Within
Antibacterial Treatment Subgroups

In the metronidazole and vancomycin subgroups, participants
who received bezlotoxumab experienced a significantly lower rate
of rCDI compared with placebo (metronidazole: RD, –9.7%; 95%
CI, –16.4% to –3.1%; vancomycin: RD, –15.4%; 95% CI, –22.7% to
–8.0%). In the fidaxomicin subgroup, there was a trend for a reduction in rCDI rate in bezlotoxumab-treated participants compared
with placebo (RD, –11.9%; 95% CI, –38.1% to 14.3%) (Figure 2).
Other Outcomes

All-cause and CDI-related rehospitalization was similar across
antibiotic treatment subgroups for placebo-treated participants,
but there was a higher rate of CDI-associated readmissions
in vancomycin-treated participants (vancomycin, 14.0%;
metronidazole, 8.3%; fidaxomicin, 7.7%) (Table 3). CDI-related
rehospitalizations were lower for bezlotoxumab compared with
placebo in the metronidazole (4.9% vs 8.3%) and vancomycin
subgroups (5.2% vs 14.0%) (Table 3). Mortality rates were
similar regardless of antibiotic treatment or bezlotoxumab
administration (Table 3).
DISCUSSION

rCDI remains a central unmet need in the management of CDI,
with no uniformly effective treatment approach. Following
significant revisions to treatment guidelines, vancomycin and
fidaxomicin are the recommended antibacterial drugs for the
treatment of CDI [1]. However, studies have demonstrated
that the choice of antibacterial drug treatment may affect the
likelihood of further rCDI episodes [8–10]. In MODIFY I/II,
bezlotoxumab was shown to substantially reduce the rate of
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Age, years

38.4% of participants in the vancomycin subgroup (RD, 10.4%;
95% CI, 2.9% to 17.9%) (Figure 2). However, the difference in
rCDI rate between antibacterial treatment groups decreased
when patients were stratified by history of CDI: in participants
with primary CDI, 25.5% of metronidazole-treated participants
experienced rCDI compared with 27.8% of vancomycin-treated
participants (RD, 2.4%); in participants with ≥1 episode of CDI
in the past 6 months, 46.2% of metronidazole-treated participants experienced rCDI compared with 50.4% of vancomycintreated participants (RD, 4.2%). Following adjustment for prior
CDI history, the overall difference (vancomycin minus metronidazole) in the proportion of participants who experienced
rCDI (among those with ICC) was 2.8% (95% CI, –5.0% to
10.8%). The relationship between CDI history in the previous
6 months and occurrence of rCDI in placebo-treated participants with ICC is presented in Figure 3. As plots for metronidazole and vancomycin fall to the trend line, this suggests that
the difference in the observed rCDI rates between these subgroups is largely explained by a baseline difference between the
2 cohorts.

100

Difference (95% CI)a:
–0.3 (–5.9, 5.3)

Difference (95% CI)a:
9.7 (–11.0, 31.3)
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–0.3 (–4.3, 3.7)
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20
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26

781
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Metronidazole
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Fidaxomicin

All subjects

Antibacterial drug treatment for CDI
Bezlotoxumab

Placebo

Figure 1. Proportion of participants with initial clinical cure (mITT population). aBased on the Miettinen and Nurminen method. Abbreviations: CDI, Clostridioides difficile
infection; CI, confidence interval, mITT, modified intent-to-treat.

rCDI in participants receiving metronidazole, vancomycin, or
fidaxomicin over 12 weeks compared with placebo [14].
Here, we show that the majority of participants in MODIFY
I/II received oral metronidazole or oral vancomycin, which is
consistent with the treatment guidelines that were in effect at the
time of study enrollment [5]. We also demonstrate that the rate of

50

Difference (95% CI)a:
–9.7 (–16.4, –3.1)

ICC was ~80% in participants who received placebo, regardless
of whether metronidazole, vancomycin, or fidaxomicin was administered. A single infusion of bezlotoxumab did not affect
ICC rates with any antibacterial drug.
In participants receiving a placebo infusion, the rate of rCDI
was lowest in the metronidazole subgroup compared with the

Difference (95% CI)a:
–15.4 (–22.7, –8.0)

Difference (95% CI)a:
–11.9 (–38.1, 14.3)

Difference (95% CI)a:
–12.2 (–17.1, –7.4)

45
38.4

Participants with rCDI, %
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23.1
20.6
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0
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85
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114
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129

206
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297

26

20

625

621

Metronidazole

Vancomycin

Fidaxomicin

All subjects

Antibacterial drug treatment for CDI
Bezlotoxumab

Placebo

Figure 2. Proportion of participants with rCDI (clinical cure population). aBased on the Miettinen and Nurminen method. Abbreviations: CDI, Clostridioides difficile infection;
CI, confidence interval; rCDI, recurrent C. difficile infection.
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Plot represents data from N = 621 placebo
subjects with ICC (MODIFY I & II)
Trend line showing relationship
between CDI history in previous
6 months and rCDI (all cohorts)

40
Vancomycin cohort with ICC: 45.5% had CDI history
in previous 6 months; 38.4% with rCDI end point
30
Metronidazole cohort with
ICC: 12.8% had CDI history
in previous 6 months;
28.0% with rCDI end point

20
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0

10
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30
40
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Participants with CDI history in previous 6 months, %

90
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Figure 3. Relationship between CDI history in the previous 6 months and occurrence of rCDI in placebo-treated participants receiving metronidazole or vancomycin.
The relationship between CDI history in the previous 6 months and occurrence of rCDI in placebo-treated participants with ICC (n = 621) is represented by the dotted
trend line. The difference in the percentage of participants in the metronidazole and vancomycin subgroups with a history of CDI in the previous 6 months is represented
by the distance between the black (metronidazole) and gray (vancomycin) reference lines. Abbreviations: CDI, Clostridioides difficile infection; ICC, initial clinical cure;
rCDI, recurrent C. difficile infection.

vancomycin or fidaxomicin subgroups. However, this is likely
explained by some notable differences in participant characteristics between antibacterial subgroups; compared with participants in the metronidazole subgroup, participants in the
vancomycin subgroup were more likely to be older, have a
history of CDI, have ≥1 predefined risk factor for rCDI, be an
inpatient, or have severe CDI disease at baseline. Participants in
the fidaxomicin subgroup were more likely to have ≥1 episode of
CDI ever, and a higher proportion of participants had ≥3 prior

Table 3.

CDI episodes compared with those who received metronidazole
or vancomycin. These findings suggest a selection bias toward
metronidazole treatment in lower-risk participants and vancomycin or fidaxomicin treatment in higher-risk participants, thus
explaining the lower rate of rCDI in participants treated with
metronidazole.
Results from logistic regression models based on placebo
data from these trials, which have been published elsewhere,
demonstrated that the choice of antibacterial drug treatment

Proportion of Participants With 30-Day Rehospitalization and All-Cause Mortality by Treatment Arm and Antibacterial Subgroups
Bezlotoxumab

Placebo

Metronidazole

Vancomycin

Fidaxomicin

Metronidazole

Vancomycin

Fidaxomicin

All-cause

22.0
(n = 54/246)

22.7
(n = 61/269)

53.3
(n = 8/15)

25.6
(n = 62/242)

27.9
(n = 74/265)

30.8
(n = 4/13)

CDI-related

4.9
(n = 12/246)

5.2
(n = 14/269)

6.7
(n = 1/15)

8.3
(n = 20/242)

14.0
(n = 37/265)

7.7
(n = 1/13)

30-day

4.0
(n = 15/377)

3.2
(n = 12/380)

0.0
(n = 0/29)

4.2
(n = 16/380)

2.7
(n = 10/374)

3.7
(n = 1/27)

90-day

7.4
(n = 28/377)

6.3
(n = 24/380)

6.9
(n = 2/29)

8.4
(n = 32/380)

6.7
(n = 25/374)

7.4
(n = 2/27)

30-day rehospitalizations,
% (n/N)

Mortality, % (n/N)

Abbreviation: CDI, Clostridioides difficile infection.
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Participants with rCDI, %

50

CONCLUSIONS

Participants in the MODIFY I/II trials who received
bezlotoxumab with vancomycin or metronidazole demonstrated a significantly lower rate of rCDI compared with
antibiotic treatment alone. A similar effect size for reduction
in the rate of rCDI was observed for participants who received
bezlotoxumab with fidaxomicin.
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